CRC SA, now known as Synexus Clinical Research SA, is pleased to announce that its Clinical Trial Services and sites were instrumental in helping a client receiving pre-qualification of its vaccine by the World Health Organisation (WHO).
Berna Biotech/GCVC, part of the Crucell Group has received WHO pre-qualification of its fully liquid pentavalent DTPw-HepB-Hib vaccine, Quinvaxem.
CRC SA (Synexus SA) provided four sites for Berna Biotech and handled the project management and clinical execution on one of Berna Biotech's trials on this vaccine leading to WHO pre-qualification and approval. CRC SA randomised 360 babies to receive this pentavalent paediatric vaccine.
"The Clinical Trial was well organised and executed. CRC SA (Synexus SA) and their people formed a capable, competent and efficient partner in this process", commented Ursula Aeberhard, Clinical Operations Manager at Berna Biotech.